PROgastrine COlon DEpistage

Colon Cancer Screening Clinical Trial

Official title:

Dosage of Progastrin in Asymptomatic Person Participating in Colon Cancer Screening

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT03775473
• Other study ID #: PROCODE
• Status: Terminated
• Phase: N/A
• Start date: February 7, 2019
• Est. completion date: December 17, 2021

Study information

• Verified date: January 2022
• Source: ECS-Progastrin SA
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Dosage of progastrin in asymptomatic person participating in colon cancer screening

Description:

For anyone who will participate in colon screening at the Princess Grace Hospital of Monaco and who has signed the informed consent document. A blood test will be performed in addition to the screening test to assess the rate of progastrin.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 260
• Est. completion date: December 17, 2021
• Est. primary completion date: February 5, 2021
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 50 Years to 80 Years

Eligibility

Inclusion Criteria:

• participant in colon cancer screening

• signing informed consent

Exclusion Criteria:

• any major medical, psychiatric or addictive illness that would affect the informed consent process

• The consent of a representative is not allowed in this study

Related Conditions & MeSH terms

• Colon Cancer Screening
• Colonic Neoplasms
• Healthy Person

Intervention

Diagnostic Test:
• progastrin
PROCODE is an interventional study of category 2 (non-medicinal product), with a minimal risks and restrictions, involving only one blood drawn at the screening of colon cancer.

Locations

Country	Name	City	State
France	Centre Hospitalier Princesse Grace, Monaco	Montpellier	MC

Sponsors (2)

Lead Sponsor	Collaborator
ECS-Progastrin SA	Centre Hospitalier Princesse Grace

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	progastrin rate	measuring the rate of progastrin in the blood	from 15 days to 2 months (until results are obtained)